The RiverPark Large Growth Fund discussed its investment thesis on Align Technology, Inc. (NASDAQ: ALGN) in its Q2’18 investor letter. The fund sees “a significant long-term growth opportunity for the company.” In this article, we’re going to take a look at the fund’s comments about ALGN.
Here is what RiverPark said in the letter:
Align’s shares were our next top contributor for the quarter as the stock advanced 36% following another strong earnings report that exceeded estimates. Management also increased the company’s long-term growth goals at its biennial investor day in May. For the quarter, the company reported results well ahead of analyst estimates with revenue growth of 41% (an acceleration from the previous quarter’s 39% growth) and EPS growth of 38% yearover-year. Total aligner shipments grew 37% with teen aligners (Align’s less-penetrated teen orthodontia market is much larger than the adult market) leading the way with 41% year-over-year growth. iTero scanner growth also accelerated to 84%, a leading indicator of aligner shipment growth. In addition to these strong current results, the company also continues to execute well on its core initiatives of international expansion, increasing orthodontist and general dentist utilization and driving product innovation.
Despite several years of impressive results, we still see a significant long-term growth opportunity for the company. Align currently has only an 8% share of the global orthodontia market and the ease of use and effectiveness of the Invisalign product is helping the company to both take further share and grow the market. At its investor day, the company updated its long-term view of top-line growth from 15%-25% to 20%-30% (which it has exceeded and should continue to exceed for some time). The company has also executed extremely well with a disciplined balance between continuing to invest in innovation and operations while also growing operating margins, which have grown from 22% in 2015 to 24% in 2017. Although we believe that the future for the company is extremely bright, we again trimmed our ALGN position on its strong move (it is one of the more expensive holdings in the portfolio).
FS Stock/Shutterstock.com
Align Technology, Inc. (NASDAQ: ALGN) is a $29.95-billion market cap global medical device company that designs and manufactures the Invisalign system and iTero intraoral scanners and services. The company touts the Invisalign system as “the advanced clear aligner system in the world.”
Shares of Align Technology are up 61.29% since the beginning of this year. Over the past three months, the share price has jumped more 9.90%. The stock has moved up 107.18% over the past 12 months. ALGN has a consensus average target price of $409.40 and a consensus average recommendation of ‘OVERWEIGHT’, according to analysts polled by FactSet. On Wednesday, the stock was closed at $372.91.
Meanwhile, Align Technology is a popular stock among hedge funds covered by Insider Monkey. As of the end of the second quarter of 2018, there were 36 funds in our database holding shares of the company.
Before you make your next trade, you’ll want to know this.
Insider Monkey keeps track of top-rated corporate insiders and best performing hedge funds and the stocks they buy on a daily basis.
Our team has identified the five stocks that insiders and hedge funds are quietly accumulating before the broader market catches on… and none of the usual big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now…
Warren Buffett never mentions this but he is one of the first hedge fund managers who unlocked the secrets of successful stock market investing. He launched his hedge fund in 1956 with $105,100 in seed capital. Back then they weren’t called hedge funds, they were called “partnerships”. Warren Buffett took 25% of all returns in excess of 6 percent.
For example S&P 500 Index returned 43.4% in 1958. If Warren Buffett’s hedge fund didn’t generate any outperformance (i.e. secretly invested like a closet index fund), Warren Buffett would have pocketed a quarter of the 37.4% excess return. That would have been 9.35% in hedge fund “fees”.
Actually Warren Buffett failed to beat the S&P 500 Index in 1958, returned only 40.9% and pocketed 8.7 percentage of it as “fees”. His investors didn’t mind that he underperformed the market in 1958 because he beat the market by a large margin in 1957. That year Buffett’s hedge fund returned 10.4% and Buffett took only 1.1 percentage points of that as “fees”. S&P 500 Index lost 10.8% in 1957, so Buffett’s investors actually thrilled to beat the market by 20.1 percentage points in 1957.
Between 1957 and 1966 Warren Buffett’s hedge fund returned 23.5% annually after deducting Warren Buffett’s 5.5 percentage point annual fees. S&P 500 Index generated an average annual compounded return of only 9.2% during the same 10-year period. An investor who invested $10,000 in Warren Buffett’s hedge fund at the beginning of 1957 saw his capital turn into $103,000 before fees and $64,100 after fees (this means Warren Buffett made more than $36,000 in fees from this investor).
As you can guess, Warren Buffett’s #1 wealth building strategy is to generate high returns in the 20% to 30% range.
We see several investors trying to strike it rich in options market by risking their entire savings. You can get rich by returning 20% per year and compounding that for several years. Warren Buffett has been investing and compounding for at least 65 years.
So, how did Warren Buffett manage to generate high returns and beat the market?
In a free sample issue of our monthly newsletter we analyzed Warren Buffett’s stock picks covering the 1999-2017 period and identified the best performing stocks in Warren Buffett’s portfolio. This is basically a recipe to generate better returns than Warren Buffett is achieving himself.
You can enter your email below to get our FREE report. In the same report you can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12-24 months. We initially share this idea in October 2018 and the stock already returned more than 150%. We still like this investment.
Free Report Reveals
Warren Buffet's Secret Recipe
Our Price: $199FREE
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
